Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

FIRST SUBJECT ENROLLED IN THE PHASE I CLINICAL STUDY OF LAE118 (A NOVEL PI3Kα PAN-MUTANT SELECTIVE INHIBITOR)

This announcement is made by Laekna, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the "**Board**") of directors of the Company (the "**Directors**") is pleased to announce that the Group has commenced subject recruitment in the Phase I clinical study (the "**Phase I Clinical Study**") of LAE118 in China for the treatment of advanced solid tumors, and the first subject has been enrolled.

In June 2026, the Group and Vasque Bio, Inc. ("**Vasque Bio**") entered into an exclusive licensing agreement (the "**License Agreement**"). Subject to the terms and conditions of the License Agreement, the Group is entitled to receive a non-refundable and non-creditable upfront and milestone payments up to USD527 million in total, as well as tiered royalty payments ranging from single-digit to double-digit percentages on future net sales of LAE118 in the licensed territory. The Group is also entitled to the right to acquire, for no additional consideration, up to high teen percentage of Vasque Bio's outstanding common stock or cash payments in lieu of such common stock. In the event of a qualifying strategic partnering or acquisition transaction meeting certain conditions pertaining to the use of LAE118 entered by Vasque Bio, the Group shall be entitled to receive additional payments of up to 50% of such strategic transaction value.

Vasque Bio focuses primarily on the development of therapeutics for rare diseases, while the Group focuses on developing LAE118 for oncology outside the licensed territory. The Group can leverage this opportunity to accelerate the global development and commercialization of LAE118 in the licensed territory into a broader range of indications and expedite its downstream value creation (e.g. licensing, partnership, or M&A exit).

We remain focused on specific therapeutic areas where we have accumulated deep expertise and extensive know-how. To further enhance the efficiency of our discovery research and shorten preclinical timelines, we are accelerating the application of artificial intelligence (AI) across our discovery platform — from target identification and lead optimization to predictive toxicology and clinical candidate selection.

ABOUT LAE118

LAE118 is an internally discovered novel PI3Kα pan-mutant selective inhibitor. As of the date of this announcement, the Group has obtained Investigational New Drug approval from the U.S. Food and Drug Administration (the "**FDA**") and the Centre for Drug Evaluation of the National Medical Products Administration of China (the "**CDE**") for LAE118 and has initiated Phase I clinical studies.

ABOUT VASQUE BIO

Vasque Bio is a U.S.-based, clinical-stage biotechnology company dedicated to the development of therapeutics to transform the standard of care for people living with serious, life-altering rare diseases. Vasque Bio is supported by a renowned consortium of top-tier life science investors, including The Column Group ("**TCG**") and F-Prime.

RISK WARNING

LAE118 MAY ULTIMATELY NOT BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, 1 September 2026

As of the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.